Weight Watchers, now known as WW International, is embracing GLP-1 weight-loss drugs like Ozempic and Wegovy with a new platform that integrates medications with personalized nutrition, coaching, and community support. The stock surged 12.1% on this news. Despite filing for bankruptcy earlier this year, the company’s Q3 results showed a revenue increase that beat expectations, but also a significant loss per share. Analysts are cautious, with a consensus “Hold” rating and a price target of $41, indicating a potential 56.25% upside. Financials are still uncertain, so caution may be advisable before investing.

Read more at Barchart: Weight Watchers Is Going All In on GLP-1 Drugs. Should You Buy WW Stock Here?